Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation

Pages: 5 Published: February 01, 2012 Report Code: GDHC0055VPT

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech.org

The viewpoint is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with G551D mutation. The viewpoint provides insights on the product clinical information and how it will bring new hopes for the CF patients.

Scope

The viewpoint provides impact analysis of approval of Kalydeco in Cystic Fibrosis Patients with G551D mutation. Its scope includes:

Epidemiology

Survival

Current Therapy Options

Unmet Need

Kalydeco – First Disease-Modifying CF Therapy

Clinical Trial Details 3

Cystic Fibrosis Therapeutic Market

Cystic Fibrosis Therapeutic Market – Drivers and Barriers

Reasons to Buy

Inputs on the current treatment options available and the clinical study of the drug. Business strategies development by understanding the current trends and future tends that will driving the global CF therapeutics market. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. How this breakthrough treatment for CF patients with G551D mutation brings new hope.

Table of Contents

1 Table of Contents

1.1 List of Figures

2 Summary

3 Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation

3.1 Cystic Fibrosis Overview

3.1.1 Disease Overview

3.1.2 Epidemiology

3.1.3 Survival

3.1.4 Current Therapy Options

3.1.5 Unmet Need

3.1.6 Kalydeco – First Disease-Modifying CF Therapy

3.1.7 Clinical Trial Details

3.1.8 Cystic Fibrosis Therapeutic Market

3.1.9 Cystic Fibrosis Therapeutic Market – Drivers and Barriers

4 Appendix

4.1 Methodology

4.1.1 Coverage

4.1.2 Secondary Research

4.1.3 Primary Research

4.1.4 Expert Panel Validation

4.2 Contact Us

4.3 Disclaimer

List of Tables

N/A

List of Figures

Figure 1: CFTR Channel Mutation and Regulation of the Chloride Channel

$500

Can be used by individual purchaser only

$1500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.